Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of niacin/laropiprant on lipoprotein(a) concentrations by baseline level and apo(a) size
2010-022258-17Phase 3Completed
- Sponsor
- Instituto Aragonés de Ciencias de la Salud
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of laropiprant and niacin in hyperlipidemia, sponsored by Instituto Aragonés de Ciencias de la Salud. Primary endpoints: Absolute reduction in lipoprotein(a) and Relative reduction in lipoprotein(a). Started Feb 2011; status: completed.
02
Drugs
laropiprantniacin
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on 2010-022258-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022258-17.